Capricor Current Deferred Revenue from 2010 to 2024
| CAPR Stock | USD 14.87 0.21 1.39% |
Current Deferred Revenue | First Reported 2006-09-30 | Previous Quarter 15.4 M | Current Value 13.1 B | Quarterly Volatility 6.2 B |
Check Capricor Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Capricor Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 2 M or Other Operating Expenses of 51.7 M, as well as many indicators such as Price To Sales Ratio of 4.94, Dividend Yield of 0.0 or PTB Ratio of 6.08. Capricor financial statements analysis is a perfect complement when working with Capricor Therapeutics Valuation or Volatility modules.
Capricor | Current Deferred Revenue |
Latest Capricor Therapeutics' Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of Capricor Therapeutics over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. Capricor Therapeutics' Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Capricor Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
Capricor Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 5,325,249 | |
| Coefficient Of Variation | 180.21 | |
| Mean Deviation | 6,901,241 | |
| Median | 4,166,667 | |
| Standard Deviation | 9,596,730 | |
| Sample Variance | 92.1T | |
| Range | 29.2M | |
| R-Value | 0.45 | |
| Mean Square Error | 79.4T | |
| R-Squared | 0.20 | |
| Significance | 0.1 | |
| Slope | 957,338 | |
| Total Sum of Squares | 1289.4T |
Capricor Current Deferred Revenue History
About Capricor Therapeutics Financial Statements
Capricor Therapeutics shareholders use historical fundamental indicators, such as Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although Capricor Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Capricor Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Capricor Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 24.3 M | 25.5 M |
Pair Trading with Capricor Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Capricor Stock
Moving against Capricor Stock
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.53 | PTN | Palatin Technologies | PairCorr |
| 0.5 | ERNA | Eterna Therapeutics | PairCorr |
| 0.44 | VALN | Valneva SE ADR | PairCorr |
| 0.42 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.
The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Capricor Stock Analysis
When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.